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Introduction
Sarcoma is a heterogeneous group of cancers of the soft tissue and bone,
and some are extremely rare. The rarity and diverse characteristics of sar-
comas has impeded the development of new treatments. Doxorubicin and
ifosfamide, either alone or in combination, have been the backbone of
metastatic soft tissue sarcomas (STS) therapy for over 15 years. Few 
effective chemotherapeutic options for the treatment of metastatic STS
beyond 1st line treatment with doxorubicin- and ifosfamide-based regi-
mens exist. Because alternative regimens for the effective treatment of
metastatic sarcoma are unavailable, varying combinations, including dox-
orubicin and/or ifosfamide, are sometimes used to treat patients who either
not candidates for use or are resistant to treatment with doxorubicin and/or
ifosfamide. Thus, a number of clinical trials have been conducted to ex-
plore alternative chemotherapeutic options. 
The reported response rate (RR) from five phase II trials of single-agent
gemcitabine treatment in patients with soft tissue and bone sarcoma was
3-18% (median RR, 5.5%) [1,2]. Docetaxel as a single agent (100 mg/m2,
IV every 3 weeks) was examined as a second line therapy in a phase II
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Purpose
The combination of gemcitabine and docetaxel (GD) is used to effectively treat patients with soft
tissue sarcoma (STS). It is widely considered that the conventional doses used are too high for
long term use and many patients must discontinue GD treatment due to its toxicity. Therefore, to
determine the appropriate dose meeting acceptable efficacy results, while minimizing toxic side
effects, we treated patients with a weekly infusion of GD (weekly GD).
Materials and Methods
A total of 22 patients presenting a variety of STSs were treated at Yonsei Cancer Center. All patients
had metastatic or recurrent cancer and had previously received doxorubicin and ifosfamide com-
bination chemotherapy. In all cases, gemcitabine (1,000 mg/m2) and docetaxel (35 mg/m2) were
administered intravenously on days 1 and 8 of a 21-day cycle. We retrospectively reviewed the
medical records of these patients.
Results
The response rate was 4.5%, with one patient diagnosed with leiomyosarcoma having a partial
response, and the disease control rate was 40.9%. The median progression-free survival (PFS)
duration was 2.7 months and the PFS was correlated with the treatment response to a weekly
GD. The median overall survival (OS) duration was 7.8 months and the OS was correlated with
histology. There was no significant difference in OS between patients who received weekly GD
as a 2nd line chemotherapy and those who received 3rd line or more. Treatment was generally
well tolerated. 
Conclusion
Weekly GD was well tolerated and showed moderate efficacy, indicating that this could be a rea-
sonable option as a salvage treatment for metastatic STS.
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ment of Cancer (EORTC) [3]. However, based on the results of several
phase II trials, the efficacy of single-agent docetaxel treatment in treating
STS appears to be quite limited with a reported RR of 0-18% (median
RR, 15%) [3-6].
Although use of gemcitabine or docetaxel as a single agent has limited
efficacy, their use in combination has been shown to be effective in patients
with STS. A clinical study by Hensley et al. [7] reported an impressive
RR of 53% in patients with predominantly uterine leiomyosarcoma using
a study regimen consisting of gemcitabine at a dose of 900 mg/m2given
over a 90-minute IV infusion on days 1 and 8, and docetaxel at a dose of
100 mg/m2 given over a 60-minute IV infusion on day 8, followed by
granulocyte-colony stimulation factor (G-CSF), during a 21 day period
[7]. In a subsequent retrospective study of 35 patients with a variety of
histologic subtypes of adult sarcoma, the patients received a similar reg-
imen but with lower dosages of gemcitabine (675 mg/m2). These patients
had previously received doxorubicin and/or ifosfamide, or were patients
for whom use of gemcitabine and docetaxel (GD) was preferable for other
medical reasons. The results of the trial demonstrated an overall RR of
43% and the responses included patients with osteosarcoma and Ewing’s
sarcoma [8]. The combination of GD also has been evaluated for use in
treatment of a variety of malignancies, with activity demonstrated in non-
small cell lung cancer (NSCLC), breast cancer, esophageal cancer and
others [9,10].
Recently, a multi-institutional, randomized phase II study in adult
metastatic STS patients demonstrated superior progression-free survival
(PFS) and overall survival (OS) for use of the combination regimen when
compared with use of gemcitabine alone. However, more than 40% of
patients receiving a combination of GD needed to discontinue the treat-
ment within 6 months of therapy due to a variety of toxicities, despite ad-
hering to recommended dose reductions [11].
Therefore, to identify the optimum dose and schedule that has both an
antitumor effect and acceptable toxicity, we administered weekly gemc-
itabine-docetaxel treatments to patients with metastatic or recurrent STS
who had failed to improve using doxorubicin and ifosfamide combination
chemotherapy. Here, we report the results of our retrospective analysis of
22 patients with advanced and refractory STS.
Materials  and  Methods
From September 2008 to March 2011, a total of 22 patients with a va-
riety of STS were treated at Yonsei Cancer Center (Table 1), and the med-
ical records of these patients were retrospectively reviewed. All patients
had metastatic or recurrent cancer and had previously received doxoru-
bicin and ifosfamide combination chemotherapy.
Following a 21 day cycle, on days 1 and 8, patients received 1,000
mg/m2gemcitabine intravenously over a 100 minutes duration, followed
immediately by 35 mg/m2intravenous docetaxel over 60 minutes. Stan-
dard prophylactic premedications were provided on day 1 and day 8 of
diphenhydramine and ondansetron or its equivalent. In addition, patients
received 8-15 mg intravenous dexamethasone, 30 minutes before doc-
etaxel was administered.
In almost all patients, radiological evaluation consisted of a computed
tomography scan and bone scintigraphy, as indicated. Response was as-
sessed every two to three cycles. When measurements were available, ra-
diographic studies and/or reports were reassessed and responses were
classified according to the Response Evaluation Criteria in Solid Tumors
(RECIST) [12]. Toxicities were evaluated using the National Cancer In-
stitute Common Terminology Criteria for Adverse Events (NCI CTCAE)
version 3.0.
RR was reported on an intent-to-treat basis. Best overall response was
defined as the best response designation recorded from the start of treat-
ment until disease progression. PFS was defined as the time from first
treatment until clinical or radiographic progression, or death. OS was re-
ported as the date of first treatment until death by any cause. PFS and OS
No. of patients (n=22)
Gender (male/female) 10/12
Median age at enrollment (range, yr) 41.5 (22-67)
Primary site
Extremity 4 (18.2)
Retroperitoneal 10 (45.5)
Visceral organs/Uterus 6 (27.3)/1 (4.5)
Other 2 (9.1)
Histology
Leiomyosarcoma 6 (27.3)
Synovial sarcoma 4 (18.2)
Liposarcoma 3 (13.6)
Malignant nerve sheath tumor 3 (13.6)
Desmoplastic small round cell tumor 2 (9.1)
Undifferentiated sarcoma 2 (9.1)
Other 2 (9.1)
Previous treatment
Radical surgery/No radical surgery 8/9
Adjuvant chemotherapy 11
Radiotherapy 8
Prior lines of chemotherapy
1 14 (63.6)
2 7 (31.8)
3 1 (4.5)
Previous chemotherapy regimen
AI (doxorubicin, ifosfamide) 22
Trabectedin 3
Other 7
ECOG performance status
0 8 (36.4)
1 12 (54.5)
2 2 (9.1)
Values are presented as number (%). ECOG, Eastern Cooperative
Oncology Group.
Table 1. Patient characteristics
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were calculated using Kaplan-Meier curves. Differences in survival 
between subgroups were compared using the log-rank test.
Results
1. Patient characteristics
Patients in the study included 12 females and 10 males with a median
age of 41.5 years (range, 22 to 67 years). The patient characteristics are
shown in Table 1.
All patients had previously received doxorubicin and ifosfamide com-
bination chemotherapy with a palliative aim. Of the 22 patients, 20 were
considered to be resistant to both drugs and 2 were unable to tolerate these
drugs due to hematologic toxicity. Weekly gemcitabine-docetaxel was
delivered as a second line chemotherapy to 14 patients (63.6%) and as a
third line or more for 8 patients (36.4%).
2. Treatment delivery
A median of 3 weekly gemcitabine-docetaxel chemotherapy courses
were delivered (range, 1 to 39 cycles) with a total of 116 courses. No
major side effects or severe complications that could be attributed to treat-
ment were reported. According to the medical records, only 4 patients
(18.2%) needed a dose reduction due to hematological toxicity. The pri-
mary justification for therapy discontinuation was progressive disease
(PD) in 20 patients. Of the other 2 patients, one withdrew due to grade 2
gastroparesis and one suffered acute renal failure due to tumor-associated
obstructive uropathy. The relative dose intensities per cycle were 90.5%
for both gemcitabine and docetaxel. Prophylactic G-CSF was not used
for any patients, while therapeutic G-CSF was used for patients with
febrile or grade 4 neutropenia. 
3. Toxicity
Treatment among the patients was generally well tolerated. Among
those exhibiting hematologic toxicity, grade 3-4 neutropenia occurred in
Table 2. Reported toxicities
Non-hematologic toxicity Hematologic toxicity
Neuropathy Mucositis Hypersensitivity Neutropenia Thrombocytopenia Anemia
Grade 1-2 2 (9.1) 1 (4.5) 6 (27.3) 8 (36.4) 6 (27.3) 3 (13.6)
Grade 3-4                     0 1 (4.5) 0 4 (18.2) 3 (13.6) 1 (4.5)
Values are presented as number (%).
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Fig. 1. Progression-free survival (PFS, A) and overall survival (OS, B). CI, confidence interval.
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18.2% of cases and grade 3-4 thrombocytopenia occurred in 13.6% of
cases. Grade 3-4 mucositis occurred in 4.5% of cases. No patient discon-
tinued treatment due to toxicity or died of treatment-related toxicity. Only
4 patients (18.2%) required dose reduction, primarily due to myelosup-
pression (Table 2). An allergic reaction occurred with 6 patients when do-
cetaxel was administered, and in these cases, the infusion of docetaxel
was discontinued until the symptoms improved and then infusion was
slowly restarted. All patients were able to continue their therapy.
4. Efficacy
The antitumor effect was reported on an intent-to-treat basis. All patients
had at least one measurable lesion. Of the 22 patients reviewed, 2 were
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Fig. 2. Progression-free survival (PFS, A) and overall survival (OS, B) according to the previous lines of chemotherapy before weekly gemc-
itabine-docetaxel combination therapy.
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Fig. 3. Progression-free survival (PFS, A) and overall survival (OS, B) according to the justification for chemotherapy regimen change.
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not evaluated due to untimely death and one patient was transferred to
another hospital prior to evaluation. Among the 22 treated patients, one
patient (4.5%) with uterine leiomyosarcoma had a partial response (PR),
8 patients (36.4%) had the best response of stable disease (SD), and 11
(50%) had PD. Thus, an overall RR of 4.5% was observed while the dis-
ease control rate (DCR) was 40.9% with a median follow-up of 6.1
months (DCR: leiomyosarcoma, 66.7%; non-leiomyosarcoma, 31.3%).
The median PFS was 2.7 months (95% confidence interval [CI], 2.0 to
3.4 months) and the 12-week PFS rate was 41.9% (Fig. 1A). We per-
formed univariate analyses and did not observe any statistical association
between PFS and clinical parameters including age, sex, initial localiza-
tion, prior treatment at baseline, Eastern Cooperative Oncology Group
performance status (ECOG PS), histology, or previous lines of chemother-
apy before the GD combination (second line vs. third line or more) (Fig.
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Fig. 5. Progression-free survival (PFS, A) and overall survival (OS, B) according to histology.
Fig. 4. Progression-free survival (PFS, A) and overall survival (OS, B) according to disease response to weekly gemcitabine-docetaxel treatment.
PR, partial response; SD, stable disease.
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chemotherapy regimen change (toxicities vs. PD; p=0.027) (Fig. 3A) and
the treatment response to weekly GD treatment (PR and SD vs. PD; p <
0.0001) (Fig. 4A). Median PFS was 4.0 months (range, 2.5 to 28.2
months) in patients achieving disease control (PR and SD), compared
with 1.4 months (range, 1.2 to 2.7 months) in those not achieving disease
control.
The median survival duration was estimated to be 7.8 months (95%
CI, 0.0 to 20.6 months). The six-month survival rate was 58.7% and the
one-year survival rate was estimated to be 45.7% (Fig. 1B). No statistical
association was observed between OS and clinical parameters including
age, sex, initial localization, prior treatment at baseline, ECOG PS and
justification for the prior chemotherapy regimen change (Fig. 3B).
Interestingly, there was no significant difference in OS between patients
receiving weekly GD as a second line of treatment and those who received
a third line or more of chemotherapy (Fig. 2B). However, OS did correlate
with histology, suggesting patients with leiomyosarcoma have a higher
survival rate than other histological subtypes (p=0.026) (Fig. 5A and B).
Median OS was 24.7 months (range, 6.4 to 28.2 months) in patients with
leiomyosarcoma, compared with 4.9 months (range, 1.1 to 24.4 months)
in those with other histology subtypes. Treatment response to weekly GD
treatment (PR and SD vs. PD) (p=0.009) also correlated with OS (Fig.
4B), and disease control (PR and SD) may be predictive of survival.
Discussion
Currently, the combination of doxorubicin and ifosfamide is a standard
chemotherapeutic regimen for soft tissue sarcoma patients with a good
performance status. However, some patients are not candidates for this
therapy for reasons such as underlying cardiac dysfunction, renal insuffi-
ciency or poor performance status. Furthermore, effective chemothera-
peutic options for the treatment of metastatic sarcoma, beyond 1st line
treatment with doxorubicin- and ifosfamide-based regimens, remain lim-
ited.
Gemcitabine (20,20-diflurodeoxycitidine) is a fluorinated analog of the
nucleoside, deoxycytidine. The active form, obtained by phosphorylation,
inhibits ribonucleotide reductase as a diphosphate, while the triphosphate
is incorporated into DNA and blocks DNA synthesis [13-16]. Docetaxel
stabilizes tubulin and inhibits mitotic and interphase cellular functions
[17,18]. Therefore, combination of GD may provide synergistic effects
due to their complementary mechanisms of action whereby gemcitabine
induces cell cycle arrest and docetaxel promotes cell death [19]. The com-
bination of GD has been shown in recent studies to be effective in patients
with STS [7,8,11,20]. In these studies, IV infusion of docetaxel at a dose
of 100 mg/m2was administered every 3 weeks. Generally, the docetaxel
dose was used to treat patients with NSCLC, breast cancer and others as
a one hour IV infusion administered once every 3 weeks (3-weekly) at a
dose ranging from 60-100 mg/m2. In Asia, conventional 3-weekly doses
of 60-75 mg/m2have typically been administered due to decreased toler-
ability compared to non-Asian patients [21]. However, in the 3-weekly
docetaxel schedule, neutropenia occurs in virtually all patients, and grade
3/4 neutropenia occurs in 65-75% of patients given 60-75 mg/m2. Hence,
several clinical trials have examined docetaxel administered as weekly
doses of 35-40 mg/m2, which demonstrated significantly lower toxicity
profiles, especially for hematologic toxicity, as well as efficacy similar to
the 3-weekly schedule [22-25]. Our patients were heavily treated, and we
administered docetaxel at a weekly dose of 35 mg/m2.
In a phase II trial including 29 patients with unresectable uterine
leiomyosarcoma and 5 patients with STS of other primary sites, an overall
RR of 53% (95% CI, 35 to 70%) with acceptable toxicity results was very
encouraging.  This  study  was  impressive  in  its  demonstration  of
leiomyosarcoma as a subtype that is relatively sensitive to this chemother-
apy combination [7]. Several subsequent studies have observed antitumor
activity using combinations of GD in patients with leiomyosarcoma.
Therefore, the efficacy of GD depends on histology. While the OS was
superior in patients with leiomyosarcoma compared to those with other
histological subtypes in our study (p=0.026) (Fig. 4B), it is not known
why leiomyosarcoma and malignant fibrous histiocytoma/high-grade un-
differentiated pleomorphic sarcoma respond better to this combination
[8,11,20].
We anticipated the response or survival of patients who received weekly
GD as a second line to be superior than those who received it as third line
or more. Interestingly, there was no significant difference in the OS be-
tween the two groups (Fig. 2B). We suspect many patients who received
GD as a third line or more had leiomyosarcoma. But, almost all patient
who received it as a third line or more had non-leiomyosarcoma (87.5%),
and only one patient had leiomyoma (12.5%). In other studies, the overall
RR or OS was similar both for patients who had received prior treatments
and for those who were treated with GD as a first line therapy [7,8,20].
The reason of this point is not clear, but we suppose it’s because the com-
bination of GD have antitumor effect in a different way than other
chemotherapeutic agents (doxorubicin and ifosfamide), and the patents
with relatively good performance received third line treatment.  
Our weekly GD treatment was well tolerated, and grade 3-4 neutrope-
nia and thrombocytopenia occurred in only 18.2% and 13.6% of cases.
In previous trials, the rate of grade 3-4 neutropenia and thrombocytopenia
were 20-40%, though those who were treated with GD as a 1st line ther-
apy were included [7,11]. In comparison, our study demonstrated an ex-
tremely low toxicity profile. Also, no major side effects or severe
complications that could be attributed to weekly GD administration were
reported. This suggests that a weekly divided dose of docetaxel may be
more tolerable. In addition, there may be a possibility of increasing dose
intensity with proper G-CSF support.
C onclusion
Weekly infusions of GD were very well tolerated and showed moderate
efficacy as second and third line treatments, indicating that this could be
Cancer Res Treat. 2012;44(1):43-49
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a reasonable salvage treatment option for metastatic STS, refractory to
doxorubicin and ifosfamide. The fact that the weekly GD treatment in
this study resulted in better survival for patients with leiomyosarcoma
highlights the importance of selecting histology subtype-specific treat-
ment. The fact that there was no significant difference in OS between the
patients receiving second or third line treatment or more, illustrated the
possibility for use of weekly GD as an effective salvage treatment for
heavily treated metastatic STS patients. However, fewer patents were en-
rolled in this study than in the other studies, and our patients were selected
based on good performance and organ function for this salvage treatment,
criteria which could become the basis for a prospective validation study.
With the result of our study in mind, future salvage treatment studies
should be conducted for third line or greater patients, including a higher
prophylactic G-CSF treatment dose in patients with proper host status.
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